Loading...
•
Mar 31, 2024
Taysha Gene Therapies Q1 2024 Earnings Report
Reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Key Takeaways
Taysha Gene Therapies reported a net loss of $24.1 million, or $0.10 per share, for the first quarter ended March 31, 2024. As of March 31, 2024, Taysha had $124.0 million in cash and cash equivalents, which is expected to support planned operating expenses and capital requirements into 2026. The company is advancing its TSHA-102 program in clinical evaluation for Rett syndrome and received RMAT designation for TSHA-102 from the FDA.
Completed dosing in cohort one of REVEAL Phase 1/2 adolescent and adult trial, with longer-term data supporting the safety profile and durable response of TSHA-102.
Enrolled first patient in cohort two of REVEAL Phase 1/2 adolescent and adult trial with dosing scheduled for Q2 2024.
Dosed second pediatric patient in cohort one of REVEAL Phase 1/2 pediatric trial in Q1 2024.
FDA granted Regenerative Medicine Advanced Therapy designation for TSHA-102 following review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL trials.
Taysha Gene Therapies
Taysha Gene Therapies
Forward Guidance
Taysha anticipates several milestones for 2024, including the dosing of the first patient in cohort two of the REVEAL Adolescent and Adult Trial in Q2 2024, updates on safety and efficacy data from both the REVEAL Adolescent and Adult Trial and the REVEAL Pediatric Trial, and initial data from cohort two expected in the second half of 2024.
Positive Outlook
- Dosing of the first patient in cohort two (high dose) of 1x1015 total vg scheduled for the second quarter of 2024
- Update on available safety and efficacy data from completed cohort one (low dose) of 5.7x1014 total vg expected in mid-2024
- Initial available safety and efficacy data from cohort two expected in the second half of 2024
- Initial available safety and efficacy data from cohort one (low dose) of 5.7x1014 total vg expected in mid-2024
- Initial available safety and efficacy data from cohort two (high dose) of 1x1015 total vg expected in the second half of 2024